Zomedica Corp (ZOMDF) Fair Value & Analysis
Healthcare · US · Market cap $98.0M
Zomedica Corp
ZOMDF · US
Fair value as of: Jul 31, 2026
From 1 valuation models · updated 11 days ago
Fair value updated Jul 31, 2026, revised from $0.0523 to $0.0556 (+6.4%) since Jun 26, 2026. Share price −9.3% over the past month.
Below-average quality, and screening another 33% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case ($0.0722). The favourable scenario is already priced in.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- Solid but not exceptional quality (45/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 31, 2026.
How to read this chart
60‑month range $0.0300 – $1.06 · fair‑value band $0.0473 – $0.0722 · the $0.0835 price screens above the $0.0556 fair value. Dashed = 300-day average. As of Jul 31, 2026.
Analysis
Zomedica Corp (ZOMDF) currently trades at $0.0835, while our model-based Fair Value estimate is $0.0556, implying the stock looks roughly 33.4% overvalued today. The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Zomedica Corp generated revenue of $34.3M at a net margin of -65.8%. Revenue grew 35.4% year over year. It earns a return on equity of -18.6%. Fundamentals as of Jul 31, 2026
Our scenario range runs from $0.0473 (bear case) to $0.0722 (bull case); at $0.0835, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 47% below its 52-week high and 139% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -33%, ZOMDF screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when ZOMDF reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 31, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 44 · Market factors (momentum, volatility) 42
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals.
Full company description
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. It offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. The company provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, Assisi EquiLoop, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Zomedica Corp reported revenue of $32.0M in FY2025 versus $4.1M in FY2021, a compound +66.8%/yr. Reported net income was −$81.9M in FY2025.
ZOMDF screens 33% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 31, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare Zomedica Corp with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Zomedica Corp (ZOMDF) overvalued or undervalued?
What is the fair value of ZOMDF?
What is the quality score of ZOMDF?
What is the revenue of Zomedica Corp (ZOMDF)?
What is the net profit margin of ZOMDF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Zomedica Corp and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.